Software system projects implemented with agile methods are internationally rare in the public sector. Solita’s reform for the Finnish Medicines Agency Fimea has received wide attention and interest among professionals in the field in EU countries.
“We are very happy that the Icelandic Medicines Agency has chosen us as their partner in the reform of the adverse reaction register. We are proud to help improve the safety of the pharmaceutical sector in Europe by helping to improve the quality of data and usability of digital solutions, allowing health professionals to focus on their expertise area,” said Account Director Sami Koskivaara.
“Feedback from Fimea in Finland helped convince us of Solita’s expertise in developing digital systems for the pharmaceutical sector. We are excited to have found Solita as our new cooperation partner,” said IT development manager Ásta Ágústsdóttir from the Icelandic Medicines Agency.
The reform of the adverse reaction register has aroused interest in EU countries
Solita offers health and pharmaceutical organisations modern, agile software and data solutions that increase work productivity, processing speed and employee satisfaction of expert organisations by reducing the amount of manual work and improving usability. Renewing the adverse reaction register facilitates and enhances the work of pharmaceutical authorities by enhancing operating methods with modern solutions. In addition, international standards and data contents have been revised, and adverse reaction registers must comply with the revised ICH E2B(R3) standard.
“The reform of the system marks a significant leap forward for the authorities overseeing and advancing safety in the pharmaceutical sector. While public organizations have rarely adopted agile methods for system reforms, we have had positive experiences using them to deliver efficient, well-functioning solutions that also consider the needs and preferences of employees,” said Solita’s Sami Koskivaara.
“Solita is a rapidly internationalizing company, and we now operate both in nationally significant security of supply functions and in the highly regulated international pharmaceutical sector. This enables us to further streamline collaboration between the public and private sectors while bringing modern agility to operations within the limits set by regulations,” says Risto Kaikkonen, Director of Health & Pharma at Solita.
For more information
- Solita, Sami Koskivaara, Account Director, [email protected], +358 40 737 7592
- Solita, Risto Kaikkonen, Director, Solita Health, [email protected], +358 415 368 745